chartexchange

Aquestive Therapeutics Reports Q3 2026: Revenue at $7.6M and GAAP EPS Loss of $0. ...

GuruFocus | Nov 3, 2026 4:37 PM EST

Anaphylm NDA Resubmission Accepted with PDUFA Goal Date of March 16, 2027 Related Stocks: AQST ,

Read original article